Clinical Trial Modernization Act
Summary
The Clinical Trial Modernization Act (S.4440) is an early-stage bill authorizing grants for clinical trial outreach to underrepresented populations. It has no specific funding amount and has only been referred to committee, so near-term market impact is minimal. The bill is neutral for the healthcare sector until appropriations are made.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Bill is in earliest stage (referred to committee) with no specific funding authorized.
- 2.No near-term market impact; actual spending requires separate appropriations.
- 3.CROs like IQV, ICLR, SYNH are potential beneficiaries but only if funding materializes.
Market Implications
The Clinical Trial Modernization Act is a procedural bill with no immediate market implications. Investors should monitor committee action and any subsequent appropriations bills that provide specific funding levels. Until then, the bill is noise for healthcare and technology sectors.
Full Analysis
The Clinical Trial Modernization Act was introduced in the Senate on April 29, 2026, by Senator Tim Scott (R-SC) with one cosponsor, and referred to the Committee on Finance. It is in the earliest legislative stage. The bill authorizes the Secretary of HHS to issue grants and contracts for community education, outreach, and recruitment activities aimed at increasing clinical trial enrollment among underrepresented populations. However, the authorization of appropriations is for 'such sums as may be necessary' for fiscal years 2027 and 2028 — no specific dollar amount is provided. This means actual funding requires a separate appropriations bill, which is uncertain at this stage.
The money trail is weak: authorization without appropriation provides no guaranteed spending. The mechanism is grant-based, not direct procurement or tax credits. Potential beneficiaries include clinical research organizations (CROs) that offer patient recruitment and decentralized trial services, such as IQVIA ($IQV), ICON ($ICLR), and Syneos Health. However, without a funding level, the revenue impact is speculative.
No real market data was provided for these tickers, so no price trend analysis is possible. The competitive landscape for CROs is mature, with these three firms dominating the market. The bill's focus on community-based and multilingual outreach could favor CROs with existing decentralized trial capabilities, but the lack of funding specifics limits conviction.
The legislative timeline is long: the bill must pass committee, be voted on by the Senate, pass the House, and be signed into law. Even then, appropriations are needed. This is a multi-year process with low probability of near-term market impact.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Grants and contracts to support community education, outreach, and recruitment for clinical trials, with priority for entities developing multilingual materials and targeting underrepresented communities.
Who must act
Entities receiving grants/contracts from the Secretary (HHS) — clinical research organizations (CROs) and community health sites.
What happens
Increased federal funding for patient recruitment and retention services, particularly for trials involving underrepresented populations, expanding the addressable market for CROs offering decentralized trial services.
Stock impact
IQVIA's clinical trial management and patient recruitment services segment (part of R&D Solutions) could see incremental revenue from new grant-funded contracts, though the authorization is for 'such sums as may be necessary' with no specific dollar amount, limiting near-term visibility.
What the bill does
Same grant program for community outreach and recruitment in clinical trials.
Who must act
CROs and community health organizations eligible for HHS grants.
What happens
Potential new revenue streams from government-funded patient recruitment contracts, especially for trials in underrepresented populations.
Stock impact
ICON's patient recruitment and site management services could benefit from grant-funded programs, but the lack of a specific appropriation amount limits the immediate revenue impact.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
CARGO Act of 2025
TRIWEST HEALTHCARE ALLIANCE CORP: $28.3M Department of Veterans Affairs Contract
THE LEWIN GROUP, INC.: $11.3M Department of Health and Human Services Contract
To amend section 495 of the Public Health Service Act to require inspections of foreign laboratories conducting biomedical and behavioral research to ensure compliance with applicable animal welfare requirements, and for other purposes.
OAK RIDGE ASSOCIATED UNIVERSITIES, INCORPORATED: $16.6M Department of Health and Human Services Contract
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $2.9B Department of Homeland Security Grant
STATE OF FLORIDA DIVISION OF EMERGENCY MANAGEMENT: $1.5B Department of Homeland Security Grant
GEORGIA EMERGENCY MANAGEMENT AND HOMELAND SECURITY AGENCY: $1.6B Department of Homeland Security Grant
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →